TERN - Madrigal and liver drug developers fall ahead of FDA decision on NASH therapy
2024-03-14 10:42:03 ET
More on Madrigal Pharma
- Madrigal Pharmaceuticals: Perceived Threat From Eli Lilly Is Overblown
- Madrigal's MASH Dilemma: Eli Lilly Enters The Fray (Rating Downgrade)
- Madrigal Pharmaceuticals: Eli Lilly's NASH Data Threatens Resmetirom's Potential
- Liver drug developers outperform as U.S. awaits first NASH drug
- Citi starts Madrigal at buy, cites upcoming FDA decision on NASH drug